VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
The University of Texas MD Anderson Cancer Center · Johnson & Johnson (United States) · +1 more institution
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
591
total citations
- FWCI
- 27.57
- Percentile
- 100%
- References
- 21
Citations per year
Authors
19- JGJianjun GaoCorresponding
The University of Texas MD Anderson Cancer Center
- JFJohn F. Ward
The University of Texas MD Anderson Cancer Center
- CACurtis A. Pettaway
The University of Texas MD Anderson Cancer Center
- LZLewis Z. Shi
The University of Texas MD Anderson Cancer Center
- SKSumit K. Subudhi
The University of Texas MD Anderson Cancer Center
Topics & keywords
Topics
Keywords
- Ipilimumab
- Prostate cancer
- Nivolumab
- Medicine
- Immunotherapy
- Immune checkpoint
- Immune system
- Prostate
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.